Clinical Trial Details

A PHASE 1B, TWO-PART STUDY OF TOLODODEKIN ALFA (ANK-101) IN COMBINATION WITH AN ANTI-PD-1/PD-L1 ANTIBODY IN PARTICIPANTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

IRB Protocol Number

ANK-101-004

Clinical Trial Categories

• Lung Cancer

Contact

Clinical Trials at 910-715-2200

How to Participate

Eligibility: Men or women, ages 18 or older, diagnosed with Stage IV non-small cell lung cancer (NSCLC)